M.A. Duchosal

Discipline

Education (2) Psychologie (1) Littératures (1) Sciences de l'information et de la communication (1) Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (29) Recensions (6)

Co-auteur

Date

Source

Mot-clé

Treatment (16) Human beings (13) Patients (12) Patients (11) survie (8) Survival (8) Leukemia (8) Mice (7) Inhibition (7) Cells (7) Number (7) thérapie (6) modèle (6) adulte (6) Therapeutics (6) Lymphomas (6) Example (6) Older people (6) adulte (6) spectacle (5) enzyme (5) Diagnosis (5) Development (5) Nicotinamide (5) Population (5) Cell death (5) Cancer cells (5) Stem cells--Transplantation (5) Use (5) Transplantation (5)

Documents écrit par M.A. Duchosal (29) | parle de M.A. Duchosal (0)

Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
S. Fratta et al. (15 mars 2023)
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
P. Biniecka et al. (16 févr. 2023)
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.
S. Matsumoto et al. (27 janv. 2023)
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
M. Obeid et al. (1 mai 2022)
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
O. ElMokh et al. (8 avr. 2022)
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
A.J. Cloux et al. (19 nov. 2019)
The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.
N. Vannini et al. (7 mars 2019)
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
D. De Goycoechea et al. (2019)
Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability.
M. Pellegrin et al. (4 sept. 2018)
Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translation.
V. Chennupati et al. (2018)
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016.
J.R. Passweg et al. (2018)
Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis.
G. Stalder et al. (2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
D.J. Klionsky et al.
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
P. Samaras et al. (2015)
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
V. Gotta et al. (2014)
A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
V. Ginet et al. (2014)
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
C.S. Breton et al. (2014)
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.
J.R. Passweg et al. (2013)
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.
M. Gavillet et al.
Gammapathies monoclonales: Utilisation des chaînes légères libres sériques.
V. Aubert et al. (2012)
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
A. Nahimana et al. (2011)
Recommendations pour le diagnostic et le traitement de la leucémie lymphoïde chronique en Suisse. 1ère partie : Diagnostic, stadification et facteurs pronostiques
M. Gregor et al. (2011)
Recommendations pour le diagnostic et le traitement de la leucémie lymphoïde chronique en Suisse. 2ème partie : Indications et stratégies thérapeutiques
M. Gregor et al. (2011)
Suivi thérapeutique de l'imatinib
V. Gotta et al. (2010)
Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
V. Frossard et al. (2009)

next